FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243899765> ?p ?o ?g. }

• W4243899765 endingPage "86" @default.
• W4243899765 startingPage "79" @default.
• W4243899765 abstract "Restless legs syndrome (RLS) is a neurological disorder characterized by bothersome symptoms associated with impaired quality of life and sleep hygiene. Rotigotine is a novel therapeutic alternative, although few studies have been published in patients on hemodialysis (HD) with RLS treated with rotigotine. (1) To establish the prevalence of RLS in our HD unit. (2) To evaluate the efficacy and safety profile of rotigotine and its effect on symptoms, quality of life and sleep hygiene in our HD population with RLS. A single-center, 12-week prospective study. Two stages (6 weeks): stage 1 (no treatment) and stage 2 (rotigotine). We analyzed: (1) Demographic data, biochemistry data, HD suitability parameters and RLS medical treatment data. (2) Lower extremity symptoms questionnaire (QS). (3) RLS severity symptoms scale (SRLSS). (4) RLS quality of life: John Hopkins RLS-QoL (JH-QoL). (5) Sleep hygiene: SCOPA Scale. We included 66 HD patients, 14 with RLS; 44.4% male, 70.2 ± 9.9 years and 111.1 ± 160.8 months on HD and 22.9% RLS. Exclusively in stage 2, a significant improvement for QS (10 ± 2.4 vs. 5.7 ± 1.0), SRLSS (21 ± 4 vs. 5.7 ± 4.6), JH-QoL (22.1 ± 4.4 vs. 4.3 ± 4.0) and SCOPA (16 ± 5.3 vs. 6.7 ± 1.9) were observed. A 77.7 and 11.1%, showed partial (>20%) and complete (>80%) remission, respectively, while 55.5% achieved “zero” symptoms. Only one patient had gastrointestinal intolerance and none experienced augmentation effect. No changes in biochemical data, suitability for dialysis or medical treatment were found. The inter-group analysis showed a significant improvement in relation to QS, SRLSS, JH-QoL and SCOPA in stage 2. RLS showed a considerable prevalence in our HD unit. Rotigotine improved clinical symptoms, quality of life and sleep hygiene in RLS patients on HD and was found to be a safe drug with minimal side effects and total therapeutic compliance. Nevertheless, future studies should be performed to confirm the benefits of rotigotine in RLS patients on hemodialysis. El síndrome de piernas inquietas (SPI) es un trastorno neurológico caracterizado por una molesta sintomatología, asociado a deterioro de calidad de vida e higiene de sueño. Rotigotina constituye una novedosa alternativa terapéutica, si bien existen escasos estudios publicados sobre rotigotina en pacientes en hemodiálisis (HD) con SPI. 1.- Establecer la prevalencia de SPI en nuestra unidad de HD. 2.- Evaluar la eficacia y el perfil de seguridad asociado a rotigotina así como su efecto sobre la sintomatología, calidad de vida e higiene del sueño en nuestra población en HD con SPI. Estudio unicéntrico, prospectivo de 12 semanas de duración. Dos fases (6 semanas): fase 1 (no tratamiento) y fase 2 (rotigotina). Analizamos: 1.- Datos demográficos, bioquímicos, parámetros de adecuación de HD y tratamiento médico relacionado con SPI. 2.- Cuestionario sobre síntomas en extremidades inferiores (QS). 3.- Escala de gravedad de los síntomas (GRLS). 4.- Calidad de vida SPI: John Hopkins RLS-QoL (JH-QoL). 5.- Higiene del sueño: Escala SCOPA. Se incluyó a 66 pacientes en HD. De ellos, 14 con SPI; el 44,4% eran hombres, con 70,2 ± 9,9 años y 111,1 ± 160,8 meses en HD. El 22,9%, con SPI. Únicamente en la fase 2 observamos una mejoría significativa para QS (10 ± 2,4 vs. 5,7 ± 1,0), GRLS (21 ± 4 vs. 5,7 ± 4,6), JH-QoL (22,1 ± 4,4 vs. 4,3 ± 4,0) y SCOPA (16 ± 5,3 vs. 6,7 ± 1,9). Un 77,7 y un 11,1% presentaron remisión parcial (>20%) y completa (>80%), respectivamente. Un 55,5% alcanzó sintomatología «cero». Un único paciente presentó intolerancia digestiva y ninguno, augmentation efect. No observamos cambios en datos bioquímicos, adecuación dialítica ni tratamiento médico. El análisis intergrupos mostró una mejoría significativa en la fase 2 con relación a QS, GRLSS, JH-QoL y SCOPA. En nuestro estudio, el SPI urémico presentó una prevalencia considerable. Rotigotina mejoró la sintomatología clínica, la calidad de vida y la higiene de sueño en los pacientes con SPI en HD, por lo que resulta ser un fármaco seguro, con mínimos efectos adversos y con cumplimento terapéutico completo. No obstante, serían necesarios futuros estudios para confirmar el beneficio de rotigotina en la población en HD con SPI." @default.
• W4243899765 created "2022-05-12" @default.
• W4243899765 creator A5015217614 @default.
• W4243899765 creator A5019682748 @default.
• W4243899765 creator A5021018136 @default.
• W4243899765 creator A5021817732 @default.
• W4243899765 creator A5024740505 @default.
• W4243899765 creator A5053219270 @default.
• W4243899765 creator A5057841262 @default.
• W4243899765 creator A5063615990 @default.
• W4243899765 creator A5077584810 @default.
• W4243899765 creator A5091051910 @default.
• W4243899765 date "2018-01-01" @default.
• W4243899765 modified "2023-10-18" @default.
• W4243899765 title "Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in hemodialysis-associated restless legs syndrome" @default.
• W4243899765 cites W1968285799 @default.
• W4243899765 cites W1972552448 @default.
• W4243899765 cites W1984638665 @default.
• W4243899765 cites W1987525065 @default.
• W4243899765 cites W2005387985 @default.
• W4243899765 cites W2013001471 @default.
• W4243899765 cites W2030617678 @default.
• W4243899765 cites W2040895462 @default.
• W4243899765 cites W2053895393 @default.
• W4243899765 cites W2056419871 @default.
• W4243899765 cites W2058182118 @default.
• W4243899765 cites W2065404670 @default.
• W4243899765 cites W2072667894 @default.
• W4243899765 cites W2091605545 @default.
• W4243899765 cites W2093831177 @default.
• W4243899765 cites W2094663096 @default.
• W4243899765 cites W2101329831 @default.
• W4243899765 cites W2104175920 @default.
• W4243899765 cites W2105044875 @default.
• W4243899765 cites W2147694941 @default.
• W4243899765 cites W2257119443 @default.
• W4243899765 cites W2337607729 @default.
• W4243899765 cites W2399064915 @default.
• W4243899765 cites W2402056635 @default.
• W4243899765 doi "https://doi.org/10.1016/j.nefroe.2017.11.017" @default.
• W4243899765 hasPublicationYear "2018" @default.
• W4243899765 type Work @default.
• W4243899765 citedByCount "2" @default.
• W4243899765 countsByYear W42438997652021 @default.
• W4243899765 countsByYear W42438997652023 @default.
• W4243899765 crossrefType "journal-article" @default.
• W4243899765 hasAuthorship W4243899765A5015217614 @default.
• W4243899765 hasAuthorship W4243899765A5019682748 @default.
• W4243899765 hasAuthorship W4243899765A5021018136 @default.
• W4243899765 hasAuthorship W4243899765A5021817732 @default.
• W4243899765 hasAuthorship W4243899765A5024740505 @default.
• W4243899765 hasAuthorship W4243899765A5053219270 @default.
• W4243899765 hasAuthorship W4243899765A5057841262 @default.
• W4243899765 hasAuthorship W4243899765A5063615990 @default.
• W4243899765 hasAuthorship W4243899765A5077584810 @default.
• W4243899765 hasAuthorship W4243899765A5091051910 @default.
• W4243899765 hasBestOaLocation W42438997651 @default.
• W4243899765 hasConcept C118552586 @default.
• W4243899765 hasConcept C126322002 @default.
• W4243899765 hasConcept C142724271 @default.
• W4243899765 hasConcept C159110408 @default.
• W4243899765 hasConcept C16568411 @default.
• W4243899765 hasConcept C1862650 @default.
• W4243899765 hasConcept C187212893 @default.
• W4243899765 hasConcept C2776245837 @default.
• W4243899765 hasConcept C2776750294 @default.
• W4243899765 hasConcept C2778063415 @default.
• W4243899765 hasConcept C2779134260 @default.
• W4243899765 hasConcept C2779424955 @default.
• W4243899765 hasConcept C2779734285 @default.
• W4243899765 hasConcept C2779951463 @default.
• W4243899765 hasConcept C2780975770 @default.
• W4243899765 hasConcept C2781210498 @default.
• W4243899765 hasConcept C2908647359 @default.
• W4243899765 hasConcept C2983189541 @default.
• W4243899765 hasConcept C547646559 @default.
• W4243899765 hasConcept C71924100 @default.
• W4243899765 hasConcept C99454951 @default.
• W4243899765 hasConceptScore W4243899765C118552586 @default.
• W4243899765 hasConceptScore W4243899765C126322002 @default.
• W4243899765 hasConceptScore W4243899765C142724271 @default.
• W4243899765 hasConceptScore W4243899765C159110408 @default.
• W4243899765 hasConceptScore W4243899765C16568411 @default.
• W4243899765 hasConceptScore W4243899765C1862650 @default.
• W4243899765 hasConceptScore W4243899765C187212893 @default.
• W4243899765 hasConceptScore W4243899765C2776245837 @default.
• W4243899765 hasConceptScore W4243899765C2776750294 @default.
• W4243899765 hasConceptScore W4243899765C2778063415 @default.
• W4243899765 hasConceptScore W4243899765C2779134260 @default.
• W4243899765 hasConceptScore W4243899765C2779424955 @default.
• W4243899765 hasConceptScore W4243899765C2779734285 @default.
• W4243899765 hasConceptScore W4243899765C2779951463 @default.
• W4243899765 hasConceptScore W4243899765C2780975770 @default.
• W4243899765 hasConceptScore W4243899765C2781210498 @default.
• W4243899765 hasConceptScore W4243899765C2908647359 @default.
• W4243899765 hasConceptScore W4243899765C2983189541 @default.
• W4243899765 hasConceptScore W4243899765C547646559 @default.
• W4243899765 hasConceptScore W4243899765C71924100 @default.

• next